tirzepatide molecular structure Chemical of (MounjaroTM). Blue: Aminoisobutyric Tirzepatide | CAS#2023788-19-2 | GIP/GLP-1

The second FDA-approved indication is for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition such as hypertension, dyslipidemia, or obstructive sleep apnea

Acronyms CrCl - Creatinine clearance GLP-1 - Glucagon-Like Peptide-1 P - Drugs with pediatric dosing Dulaglutide Trulicity Trulicity Dosage forms Single-dose pen 0.75 mg/0.5 ml 1.5 mg/0.5 ml 3 mg/0.5 ml 4.5 mg/0.5 ml Comes in carton with 4 pens Dosing Type 2 diabetes Starting: 0.75 mg once weekly Maintenance: 0.75 - 4.5 mg once weekly Max: 4.5 mg once weekly Increase to next higher dose if needed at intervals of 4 weeks May administer without regard to food If a dose is missed, administer ASAP if there are at least 3 days until the next scheduled dose If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day In each case, patients can then resume their regular once weekly dosing schedule The day of weekly administration can be changed if necessary as long as the last dose was administered 3 or more days before Kidney disease No dose adjustment is recommended in patients with renal impairment including end-stage renal disease Gastrointestinal side effects may be worse in patients with kidney disease Liver disease In a study of patients with varying degrees of liver disease, no clinically relevant change in dulaglutide pharmacokinetics was observed

Developed initially to manage blood sugar levels in individuals with type 2 diabetes, Tirzepatide has emerged as a powerful tool for weight management

People expect the pounds to drop fast when starting a new weight-loss treatment, but reality often feels slower

A citations presence does not expand permitted use beyond controlled research